Skip to main content
Figure 2 | Clinical Proteomics

Figure 2

From: Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer

Figure 2

The 132 fine needle aspirates from patients who received anthracycline and taxane-based neoadjuvant systemic therapy were subgrouped into one of the 6 groups using the decision tree from the training set. Six true patient groups were obtained (2A), Cohen's kappa score = 0.66. Beta-binomial distribution and computed joint posterior probabilities were used to evaluate the association of the prognostic groups with pCR, the posterior distribution estimates of pCR by prognostic group are shown in 2B.

Back to article page